Ikena Oncology to Participate in the 2021 Jefferies Virtual Healthcare Conference
May 26 2021 - 7:00AM
Business Wire
Ikena Oncology, Inc. (Nasdaq: IKNA), a targeted oncology company
focused on developing therapies targeting key signaling pathways
that drive the formation and spread of cancer, today announced that
management will participate in a fireside chat at the 2021
Jefferies Virtual Healthcare Conference on Wednesday, June 2, 2021
at 2:00 p.m. ET.
The fireside chat will be webcast live and can be accessed by
visiting the Investors & Media section of the company’s website
at www.ikenaoncology.com. The webcast will be archived for a period
of 30 days following the conclusion of the live event.
About Ikena Oncology
Ikena Oncology is a targeted oncology company focused on
developing cancer therapies targeting key signaling pathways that
drive the formation and spread of cancer. Ikena is advancing five
programs that include four product candidates in either clinical
development or IND-enabling studies: IK-930, a TEAD inhibitor
targeting the Hippo signaling pathway; an ERK5 inhibitor program
targeting the KRAS signaling pathway; IK-175, an AHR antagonist;
IK-412, a kynurenine-degrading enzyme; and IK-007, an EP4 receptor
antagonist. Ikena has entered into a global strategic collaboration
with Bristol-Myers Squibb Company for its IK-175 and IK-412
programs. To learn more visit www.ikenaoncology.com or follow us on
Twitter and LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210526005321/en/
Media Contact: Liza Sullivan Argot Partners 617-340-6073
liza@argotpartners.com Investor Contact: Sam Martin Argot
Partners 646-233-4302 sam@argotpartners.com
Ikena Oncology (NASDAQ:IKNA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ikena Oncology (NASDAQ:IKNA)
Historical Stock Chart
From Apr 2023 to Apr 2024